Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2021

Open Access 01-12-2021 | Metastasis | Research article

Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer

Authors: Anastasia A. Ionkina, Gabriela Balderrama-Gutierrez, Krystian J. Ibanez, Steve Huy D. Phan, Angelique N. Cortez, Ali Mortazavi, Jennifer A. Prescher

Published in: Breast Cancer Research | Issue 1/2021

Login to get access

Abstract

Background

Cancer metastasis is a complex process involving the spread of malignant cells from a primary tumor to distal organs. Understanding this cascade at a mechanistic level could provide critical new insights into the disease and potentially reveal new avenues for treatment. Transcriptome profiling of spontaneous cancer models is an attractive method to examine the dynamic changes accompanying tumor cell spread. However, such studies are complicated by the underlying heterogeneity of the cell types involved. The purpose of this study was to examine the transcriptomes of metastatic breast cancer cells using the well-established MMTV-PyMT mouse model.

Methods

Organ-derived metastatic cell lines were harvested from 10 female MMTV-PyMT mice. Cancer cells were isolated and sorted based on the expression of CD44low/EpCAMhigh or CD44high/EpCAMhigh surface markers. RNA from each cell line was extracted and sequenced using the NextSeq 500 Illumina platform. Tissue-specific genes were compared across the different metastatic and primary tumor samples. Reads were mapped to the mouse genome using STAR, and gene expression was quantified using RSEM. Single-cell RNA-seq (scRNA-seq) was performed on select samples using the ddSeq platform by BioRad and analyzed using Seurat v3.2.3. Monocle2 was used to infer pseudo-time progression.

Results

Comparison of RNA sequencing data across all cell populations produced distinct gene clusters. Differential gene expression patterns related to CD44 expression, organ tropism, and immunomodulatory signatures were observed. scRNA-seq identified expression profiles based on tissue-dependent niches and clonal heterogeneity. These cohorts of data were narrowed down to identify subsets of genes with high expression and known metastatic propensity. Dot plot analyses further revealed clusters expressing cancer stem cell and cancer dormancy markers. Changes in relevant genes were investigated across pseudo-time and tissue origin using Monocle2. These data revealed transcriptomes that may contribute to sub-clonal evolution and treatment evasion during cancer progression.

Conclusions

We performed a comprehensive transcriptome analysis of tumor heterogeneity and organ tropism during breast cancer metastasis. These data add to our understanding of metastatic progression and highlight targets for breast cancer treatment. These markers could also be used to image the impact of tumor heterogeneity on metastases.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
6.
7.
Cai Y, et al. Transcriptomic dynamics of breast cancer progression in the MMTV-PyMT mouse model. BMC Genom. 2017;18(1):185.CrossRef
8.
Zheng W, et al. Lung mammary metastases but not primary tumors induce accumulation of atypical large platelets and their chemokine expression. Cell Rep. 2019;29(7):1747-1755e4.PubMedPubMedCentralCrossRef
9.
Olsen TK, Baryawno N. Introduction to single-cell RNA sequencing. Curr Protoc Mol Biol. 2018;122(1):57.CrossRef
10.
Yeo S.K. et al. Single-cell RNA-sequencing reveals distinct patterns of cell state heterogeneity in mouse models of breast cancer. Elife 2020;9.
11.
Li H, et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat Genet. 2017;49(5):708–18.PubMedCrossRef
12.
13.
14.
15.
16.
17.
Ma J, et al. Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model. Tumour Biol. 2012;33(6):1983–96.PubMedCrossRef
18.
Kersten K, Salvagno C, de Visser KE. Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy. Front Immunol. 2015;6:516.PubMedPubMedCentralCrossRef
19.
Crabtree JS, Miele L. Breast cancer stem cells. Biomedicines. 2018;6(3):94.
20.
Fico F, et al. Breast cancer stem cells with tumor- versus metastasis-initiating capacities are modulated by TGFBR1 inhibition. Stem Cell Rep. 2019;13(1):1–9.CrossRef
21.
Lobba AR, et al. Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines. Cytometry A. 2012;81(12):1084–91.PubMedCrossRef
22.
Haynes B, et al. Breast cancer complexity: implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Rev. 2017;36(3):547–55.PubMedPubMedCentralCrossRef
23.
24.
25.
26.
Liao X, Makris M, Luo XM. Fluorescence-activated cell sorting for purification of plasmacytoid dendritic cells from the mouse bone marrow. J Vis Exp. 2016;117:54641.
27.
Marhaba R, et al. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med. 2008;8(8):784–804.PubMedCrossRef
28.
Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12(3):954–61.PubMedPubMedCentral
29.
30.
Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinf. 2011;12:323.CrossRef
31.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40.PubMedCrossRef
32.
Bray NL, et al. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34(5):525–7.CrossRefPubMed
33.
Hen O, Barkan D. Dormant disseminated tumor cells and cancer stem/progenitor-like cells: Similarities and opportunities. Semin Cancer Biol. 2020;60:157–65.PubMedCrossRef
34.
Cardoso F, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–29.PubMedCrossRef
35.
van 't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.
36.
37.
Takebe N, Warren RQ, Ivy SP. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res. 2011;13(3):211.PubMedPubMedCentralCrossRef
38.
Feng Y, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106.PubMedPubMedCentralCrossRef
39.
Evans MK, et al. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis. 2016;7:2073.CrossRef
40.
Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8(1):61–70.PubMedCrossRef
41.
Wasinski B, et al. Discoidin domain receptors, DDR1b and DDR2, promote tumour growth within collagen but DDR1b suppresses experimental lung metastasis in HT1080 xenografts. Sci Rep. 2020;10(1):2309.PubMedPubMedCentralCrossRef
42.
Xu X, et al. Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res. 2005;65(1):130–6.PubMedCrossRef
43.
Morandi EM, et al. ITGAV and ITGA5 diversely regulate proliferation and adipogenic differentiation of human adipose derived stem cells. Sci Rep. 2016;6:28889.PubMedPubMedCentralCrossRef
44.
45.
Atsumi T, et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res. 2002;62(20):5881–7.PubMed
46.
47.
Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–84.PubMedCrossRef
48.
49.
50.
Westbrook JA, et al. CAPG and GIPC1: breast cancer biomarkers for bone metastasis development and Treatment. J Natl Cancer Inst. 2016;108(4):djv360.PubMedCentralCrossRef
51.
52.
53.
Ross C, et al. Metastasis-specific gene expression in autochthonous and allograft mouse mammary tumor models: stratification and identification of targetable signatures. Mol Cancer Res. 2020;18(9):1278–89.PubMedPubMedCentralCrossRef
54.
Wood SL, Brown JE. Personal medicine and bone metastases: biomarkers, micro-RNAs and bone metastases. Cancers (Basel). 2020;12(8):2109.PubMedCentralCrossRef
55.
Yang C, et al. Inducible formation of leader cells driven by CD44 switching gives rise to collective invasion and metastases in luminal breast carcinomas. Oncogene. 2019;38(46):7113–32.PubMedCrossRef
56.
57.
58.
Sachidanandam R, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409(6822):928–33.
59.
Chen K, Fraley SI. Abstract 5706: Identifying regulators of cancer heterogeneity with phenotypic sorting and single cell sequencing. Can Res. 2020;80(16 Supplement):5706.CrossRef
60.
Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–602.
61.
62.
Nagai T, et al. Tactics of cancer invasion: solitary and collective invasion. J Biochem. 2020;167(4):347–55.PubMedCrossRef
63.
64.
Iliopoulos D, et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA. 2011;108(4):1397–402.PubMedPubMedCentralCrossRef
65.
Plaks V, Kong N, Werb Z. The cancer stem cell niche: HOW essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16(3):225–38.PubMedPubMedCentralCrossRef
66.
Yi Y, et al. Transcriptional suppression of AMPKalpha1 promotes breast cancer metastasis upon oncogene activation. Proc Natl Acad Sci USA. 2020;117(14):8013–21.PubMedPubMedCentralCrossRef
67.
68.
69.
70.
71.
Kim RS, et al. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS ONE 2012;7(4):e35569.
72.
73.
Ibrahim SA, et al. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer. 2017;16(1):57.PubMedPubMedCentralCrossRef
74.
Gotte M, et al. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res. 2006;26(1B):621–7.PubMed
75.
Grimm D, et al. The role of SOX family members in solid tumours and metastasis. Semin Cancer Biol. 2020;67(Pt 1):122–53.PubMedCrossRef
76.
77.
Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399–405.PubMed
78.
Lifsted T, et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer. 1998;77(4):640–4.PubMedCrossRef
79.
Le Voyer T, et al. An epistatic interaction controls the latency of a transgene-induced mammary tumor. Mamm Genome. 2000;11(10):883–9.PubMedCrossRef
Metadata
Title
Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer
Authors
Anastasia A. Ionkina
Gabriela Balderrama-Gutierrez
Krystian J. Ibanez
Steve Huy D. Phan
Angelique N. Cortez
Ali Mortazavi
Jennifer A. Prescher
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-021-01468-x

Other articles of this Issue 1/2021

Breast Cancer Research 1/2021 Go to the issue

Research article

High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer

Research article

Low thyroid hormone receptor alpha-2 (THRα-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality

Research article

Regulatory T lymphocyte infiltration in metastatic breast cancer—an independent prognostic factor that changes with tumor progression

Research article

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

Research article

Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

Research article

Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits